External broker reports(aggregated public sources), CMB International

CMB International

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

External broker reports(aggregated public sources)

Equity Bottom-Up

Dingdang Health Technology Gro / Equity Bottom-Up

<ul><li>We expect Dingdang to experience robust revenue growth of +24% YoY in 2022E, despite the negative impacts from COVID on new store openings and sales of “four-type medicines”.</li><li>Going forward, we see Dingdang’s business growth to accelerate to +29%/ +27% YoY in 2023E/ 24E with continuous cost saving from fulfilment and admin expenses, considering the post-pandemic business resumption and the growing penetration rate of online medicine purchasing in China retail pharmacy.</li><li>Accordingly, we forecast Dingdang to book adjusted net losses of RMB192mn/ RMB94mn in 2022E/ 23E and adjusted net profits of RMB29mn in 2024E</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We expect Dingdang to experience robust revenue growth of +24% YoY in 2022E, despite the negative impacts from COVID on new store openings and sales of “four-type medicines”.Going forward, we see Dingdang’s business growth to accelerate to +29%/ +27% YoY in 2023E/ 24E with continuous cost saving from fulfilment and admin expenses, considering the post-pandemic business resumption and the growing penetration rate of online medicine purchasing in China retail pharmacy.Accordingly, we forecast Dingdang to book adjusted net losses of RMB192mn/ RMB94mn in 2022E/ 23E and adjusted net profits of RMB29mn in 2024EContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dingdang Health (9886 HK) – 2022 preview: Continuing to enhance long-term growth logic